Evidence map›Paper›PMID 39670750›Full record

ArticleAntimicrobial agents and chemotherapy2025

Evaluation of a potent LpxC inhibitor for post-exposure prophylaxis treatment of antibiotic-resistant

Henry S Heine, Bret K Purcell, Clayton Duncan, Lynda Miller, John E Craig, Amanda Chase, Lynne Honour, Michael Vicchiarelli, George L Drusano, Pei Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Infection and drug resistance · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Henry S HeineInstitute for Therapeutic Innovation, University of Florida, Orlando, Florida, USA.ORCID 0009-0002-4746-4892
Bret K PurcellInstitute for Therapeutic Innovation, University of Florida, Orlando, Florida, USA.
Clayton DuncanValanbio Therapeutics Inc., Raleigh, North Carolina, USA.
Lynda MillerInstitute for Therapeutic Innovation, University of Florida, Orlando, Florida, USA.
John E CraigInstitute for Therapeutic Innovation, University of Florida, Orlando, Florida, USA.
Amanda ChaseInstitute for Therapeutic Innovation, University of Florida, Orlando, Florida, USA.
Lynne HonourInstitute for Therapeutic Innovation, University of Florida, Orlando, Florida, USA.
Michael VicchiarelliInstitute for Therapeutic Innovation, University of Florida, Orlando, Florida, USA.
George L DrusanoInstitute for Therapeutic Innovation, University of Florida, Orlando, Florida, USA.ORCID 0000-0001-9162-7332
Pei ZhouDepartment of Biochemistry, Duke University School of Medicine, Durham, North Carolina, USA.ORCID 0000-0002-7823-3416

Funding

US Government MCDC-18-06-16-005 under Other Transaction number W15QKN-16-9-1002
6 · The paper itself

Abstract

LPC-233 (a.k.a. VB-233) is a potent antibiotic targeting the essential enzyme LpxC in Gram-negative bacteria. We present herein the pharmacokinetics and pharmacodynamics data of LPC-233 for treating murine infections caused by

Indexed as

AmidohydrolasesAnti-Bacterial AgentsBurkholderia pseudomalleiMelioidosisPost-Exposure ProphylaxisAnimalsCeftazidimeDisease Models, AnimalFemaleMiceMicrobial Sensitivity TestsAmidohydrolasesAnti-Bacterial AgentsCeftazidimeB. pseudomalleiLPC-233LpxCmelioidosispneumonia

Identifiers

PMID39670750
PMCPMC11784359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.